BioSpace News Archive

CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company’s progress and outlook at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021.

WELL Health Technologies Corp. is pleased to announce its wholly owned subsidiary, CRH Medical Corporation, has completed two accretive transactions whereby the company has acquired a 51% stake in Northern Indiana Anesthesia Associates, LLC and an add-on practice in Bradenton, Florida which will be part of CRH affiliate, FDHS Anesthesia, LLC.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced it will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:30 a.m. ET.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:00 p.m. ET.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the following investor conferences: Jefferies Virtual Healthcare Conference on June 3, 2021 at 1:30 PM ET JMP Securities Life Sciences Conference on June 16, 2021 at 4:00 PM ET

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 8:30 a.m. ET.

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The ASCP annual meeting is being held virtually June 1-4, 2021.

TG Therapeutics, Inc. announced its participation at three upcoming virtual investor conferences.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta